New stroke drug enters early safety testing
NCT ID NCT07513233
First seen Apr 29, 2026
Summary
This early-stage study tests whether a drug called anisodine hydrobromide is safe for people having a stroke caused by a blocked large artery in the brain. About 92 adults aged 18 to 80 who are already scheduled for a clot-removal procedure will receive the drug. The main goal is to check for serious side effects like bleeding in the brain or death within 8 days of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anji County People's Hospital
RECRUITINGHuzhou, Zhejiang, 313300, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuanwu Hospital, Capital Medical University
NOT_YET_RECRUITINGBeijing, None Selected, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.